CoChat

Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy

Open access
Romano, Alessandra, Parrinello, Nunziatina Laura, Vetro, Calogero, Forte, Stefano, Chiarenza, Annalisa, Figuera, Amalia, Motta, Giovanna, Palumbo, Giuseppe Alberto, Ippolito, Massimo, Consoli, Ugo, Raimondo, Francesco Di · 2015 · British Journal of Haematology
Cited by 94

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Summary: In the attempt to find a peripheral blood biological marker that could mirror the dysregulated microenvironment of Hodgkin Lymphoma (HL), we analysed the amount of myeloid‐derived suppressor cells (MDSC), including the three main sub‐types (monocytic, granulocytic and CD 34 + fraction). The absolute MDSC count was investigated in 60 consecutive newly diagnosed HL patients and correlated with clinical variables at diagnosis and outcome. Patients received standard‐of‐care chemotherapy with the exception of interim fluorodeoxyglucose positron emission tomography (PET‐2)‐positive patients, who were switched early to a salvage regimen. All MDSC subsets were increased in HL patients compared to normal subjects (P < 0·0001) and were higher in non‐responders. However, a strong prognostic significance was limited to immature (CD 34+) MDSC. A cut‐off level of 0·0045 × 10 9/l for CD 34+MDSC resulted in 89% (95% confidence interval [CI] 52–99%) sensitivity and 92% (95% CI 81–98%) specificity. The positive predictive value to predict progression‐free survival was 0·90 for PET‐2 and 0·98 for CD 34+MDSC count; the negative predictive value was 0·57 for PET‐2 and 0·73 for CD 34+MDSC. PFS was significantly shorter in patients with more than 0·0045 × 10 9 CD 34+MDSC cells/l at diagnosis and/or PET‐2 positivity (P < 0·0001). In conclusion, all circulating MDSC subsets are increased in HL; CD 34+MDSC predict short PFS, similarly to PET‐2 but with the advantage of being available at diagnosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.13198

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 94

Metadata

Authors
Romano, A., Parrinello, N. L., Vetro, C., Forte, S., Chiarenza, A., Figuera, A., Motta, G., Palumbo, G. A., Ippolito, M., Consoli, U., & Raimondo, F. D.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2014-11-07
Volume
168
Issue
5
Pages
689-700
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2105565011
Cited by
94
References
6
FWCI
4.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy. https://app.cochat.ai/papers/10.1111/bjh.13198
The paper
Romano, A., Parrinello, N. L., Vetro, C., Forte, S., Chiarenza, A., Figuera, A., Motta, G., Palumbo, G. A., Ippolito, M., Consoli, U., & Raimondo, F. D. (2015). Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy. British Journal of Haematology. https://doi.org/10.1111/bjh.13198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.